Clinical trial NCT03469921: Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
Official title: Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Haemopathies
Acute Leukemia
Non-hodgkin Lymphoma
Hodgkin Lymphoma
Keywords: Malignant haemopathies
Acute Leukemia
Non-hodgkin Lymphoma
Hodgkin Lymphoma
Young adults
Adolescent
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2018-03-19
Enrollment: 602
Sex: ALL
Minimum age (years): 15
Maximum age (years): 30
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cohort of young adult patients and adolescents aged 15 to 30, carriers of hematological malignancies, and supported between 2000 and 2016

Brief summary: Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Detailed description: The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Eligibility criteria: Inclusion Criteria:

* Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016.

Exclusion Criteria:

* Not applicable

Primary outcomes:
measure: Global Survival
timeFrame: 15 years
measure: Survival without event
timeFrame: 15 years
measure: Progression-free survival
timeFrame: 15 years
Secondary outcomes:
measure: Epidemiological distribution by pathology compared to the adult population over 30 years
timeFrame: 1 day
measure: Descriptive analysis of the characteristics of the disease at diagnosis by pathology
timeFrame: 15 years
measure: Descriptive analysis of treatments by pathology
timeFrame: 15 years
measure: Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
timeFrame: 15 years
measure: Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
timeFrame: 15 years
measure: Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology
timeFrame: 15 years
measure: Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology.
timeFrame: 15 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli Calmettes
state: Bouches Du Rhone
Study officials:
affiliation: Institut Paoli-Calmettes
name: Diane COSO
role: PRINCIPAL_INVESTIGATOR
References: